Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses

Abstract Background Treatment response varies significantly among rectal cancer patients. Tumor can show complete regression, stationary appearance, or even tumour progression during the treatment. It is also widely known that the rate of local recurrence is variable. Precise risk stratification of tumor aggressiveness is required for better per patient tailored treatment plan and predicting the overall prognosis of rectal cancer patients The aim of this study was to assess different parameters of baseline [18F] fluorodeoxyglucose positron emission tomography/computed tomography [(18F) FDG-PET/CT] as a non-invasive tool in predicting aggressiveness of the rectal cancer. Results Overall, 33 patients were included [19 moderately differentiated adenocarcinoma, 10 poorly differentiated adenocarcinoma and 4 mucinous adenocarcinomas (MAC)]. SUV estimates (SUV max, SUV mean) were greater in the moderately adenocarcinoma group (p = 0.003 and p = 0.019, respectively). MTV and TLG values were similar between the three histopathological groups (p = 0.763 and p = 0.701, respectively). There was no correlation between SUVmax of primary tumor and MTV (r = 0.034; p = 0.849). However, SUVmax and TLG were significantly correlated (r = 0.517; p = 0.002). Strong correlation between tumor size and MTV (r = 0.489; p = 0.003), and TLG (r = 0.506; p = 0.003) were observed. No significant association was found between MTV and TLG and the clinical stage of rectal cancer. Conclusion Baseline 18F-FDG PET/CT parameters cannot be used alone as a non-invasive diagnostic technique in assessing aggressiveness and prognosis in patients with primary rectal cancer, and further clinical studies are needed before considering the prognostic role of FDG-PET/CT in rectal cancer.

Download Full-text

F-18 FDG PET/CT in Tuberculosis: Non-Invasive Marker of Therapeutic Response to Antitubercular Therapy

International Journal of Nuclear Medicine Research ◽

10.15379/2408-9788.2015.02.01.5 ◽

2015 ◽

Vol 2 (1) ◽

pp. 22-24 ◽

Cited By ~ 2

Author(s):

Koramadai Kamaleshwaran ◽

◽

Ajit Shinto ◽

Sudhakar Natarajan ◽

Vyshakh Mohanan ◽

...

Keyword(s):

Fdg Pet ◽

Therapeutic Response ◽

Antitubercular Therapy ◽

Non Invasive ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

NON-INVASIVE ASSESSMENT OF ATHEROSCLEROTIC CAROTID PLAQUES BY 18F-FLUORODEOXYGLYCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (18F-FDG PET/CT) IMAGING AND MICROWAVE RADIOMETRY (MWR): VALIDATION WITH HISTOPATHOLOGICAL FINDINGS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(16)31814-9 ◽

2016 ◽

Vol 67 (13) ◽

pp. 1813

Author(s):

Georgios Benetos ◽

Konstantinos Toutouzas ◽

Iosif Koutagiar ◽

George Agrogiannis ◽

Aleksandros Georgakopoulos ◽

...

Keyword(s):

Computed Tomography ◽

Positron Emission Tomography ◽

Fdg Pet ◽

Microwave Radiometry ◽

Emission Tomography ◽

Non Invasive ◽

Positron Emission ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Download Full-text

Is <sup>18</sup>F-FDG-PET/CT a Valid Non-Invasive Predictor for Regression Grade after Neoadjuvant Treatment in Patients with NSCLC Stage III?

Journal of Cancer Therapy ◽

10.4236/jct.2014.56061 ◽

2014 ◽

Vol 05 (06) ◽

pp. 531-541

Author(s):

Natalie Desiree Klass ◽

Richard P. Baum ◽

Michael Schmuecking ◽

Norbert Presselt ◽

Klaus-Michael Mueller ◽

...

Keyword(s):

Fdg Pet ◽

Neoadjuvant Treatment ◽

Stage Iii ◽

Non Invasive ◽

Pet Ct ◽

Fdg Pet Ct ◽

Regression Grade

Download Full-text

18F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response

The International Journal of Tuberculosis and Lung Disease ◽

10.5588/ijtld.12.0010 ◽

2012 ◽

Vol 16 (9) ◽

pp. 1180-1185 ◽

Cited By ~ 60

Author(s):

V. Martinez ◽

M. A. Castilla-Lievre ◽

C. Guillet-Caruba ◽

G. Grenier ◽

R. Fior ◽

...

Keyword(s):

Fdg Pet ◽

Therapeutic Response ◽

Non Invasive ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Improved non-invasive T-Staging in non-small cell lung cancer by integrated18F-FDG PET/CT

Nuklearmedizin ◽

10.1055/s-0037-1616618 ◽

2007 ◽

Vol 46 (01) ◽

pp. 09-14 ◽

Cited By ~ 20

Author(s):

S. Pauls ◽

A. K. Buck ◽

K. Hohl ◽

G. Halter ◽

M. Hetzel ◽

...

Keyword(s):

Fdg Pet ◽

Tumor Stage ◽

Small Cell ◽

Imaging Modalities ◽

Small Cell Lung ◽

Non Invasive ◽

T Stage ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Summary Aim: In this prospective study, reliability of integrated 18F-FDG PET/CT for staging of NSCLC was evaluated and compared to MDCT or PET alone. Patients, methods: 240 patients (pts) with suspected NSCLC were examined using PET/CT. Of those patients 112 underwent surgery comprising 80 patients with NSCLC (T1 n = 26, T2 n = 37, T3 n = 11, T4 n = 6). Imaging modalities were evaluated independently. Results: MDCT, PET and PET/CT diagnosed the correct T-stage in 40/80 pts (50%; CI: 0.39-0.61), 40/80 pts (50%; CI: 0.39-0.61) and 51/80 pts (64%; CI: 0.52-0.74), respectively, whereas equivocal T-stage was found in 15/80 pts (19%; CI: 0.11-0.19), 12/80 pts (15%; CI: 0.08-0.25) and 4/80 pts (5%; CI: 0.01-0.12), respectively. With PET/CT, T-stage was more frequently correct compared to MDCT (p = 0.003) or PET (p = 0.019). Pooling stages T1/T2, T-stage was correctly diagnosed with MDCT, PET and PET/CT in 54/80 pts (68%; CI: 0.56-0.78), 56/80 pts (70%; CI: 0.59-0.80) and 65/80 pts (81%; CI: 0.71-0.89). T3 stage was most difficult to diagnose. T3 tumors were correctly diagnosed with MDCT in 2/11 pts (18%; CI: 0.02-0.52) versus 0/11 pts (0%; CI: 0.00-0.28) with PET and 5/11 pts (45%; CI: 0.17-0.77) with PET/CT. In all imaging modalities, there were no equivocal findings for T4 tumors. Of these, MDCT found the correct tumor stage in 4/6 pts (67%; CI: 0.22-0.95), PET in 3/6 pts (50%; CI: 0.12-0.88) and PET/ CT in 5/6 pts (83%; CI: 0.36-0.99). Conclusion: Integrated PET/CT was significantly more accurate for T-staging of NSCLC compared to MDCT or PET alone. The advantages of PET/CT are especially pronounced combining T1- and T2-stage as well as in advanced tumors.

Download Full-text